ResearchSafe

P21 (P21 (CNTF-Derived Tetrapeptide))

Category: Cognitive & Nootropic. Status: Research compound.

A CNTF-derived peptide promoting neurogenesis that crosses BBB. Stimulates hippocampal neurogenesis without CNTF appetite-suppressing effects.

How it works

Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation.

Key facts

  • Molecular weight: ~450 Da
  • Half-life: 4-6 hours
  • Bioavailability: Moderate (crosses BBB)
  • Storage: Lyophilized: -20°C.

Dosing overview

  • Typical dose: 50-100 mcg/kg
  • Frequency: Daily
  • Duration: 4-8 weeks
  • Route: Intranasal or Subcutaneous

Reported benefits

  • Hippocampal neurogenesis
  • BDNF increase
  • Cognitive enhancement
  • BBB penetrant
  • No appetite suppression
  • Dendritic branching

Possible side effects

  • Limited safety data
  • Nasal irritation
  • Mild headache

Research

  • P21 enhances hippocampal neurogenesis and cognition (2021): Increased progenitor proliferation by 150% and improved water maze performance by 40% in aged rats.
  • CNTF-derived P21 for AD prevention (2022): Prevented tau hyperphosphorylation and synaptic loss in transgenic AD mice.

Compare P21

Community discussions about P21

Research and educational reference only. Not medical advice.